Baxter International Inc.

baxter.com

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

DELFI DIAGNOSTICS SELECTED AS THE LIQUID BIOPSY PARTNER FOR 4-IN-THE-LUNG-RUN: A LARGE-SCALE EUROPEAN LUNG CANCER SCREENING STUDY

Delfi Diagnostics | September 12, 2022

news image

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR. Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their in...

Read More

Research

BIGHAT BIOSCIENCES COMPLETES FIRST STAGE OF RESEARCH COLLABORATION WITH AMGEN

BigHat Biosciences, Inc. | January 12, 2022

news image

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s antibody design platform integrates a high-speed characterization with AI/ML tech...

Read More

RGENTA THERAPEUTICS LAUNCHES WITH $20 MILLION SEED INVESTMENT

BioSpace | April 02, 2020

news image

Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, announced today that it closed a $20 Million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China. Rounding out the series seed syndicate are two additional investors, Kaitai Capital and Legend Star Fund. The company has assembled a world-class team of small-molecule drug developers and an exceptional Scientific A...

Read More

AI

BENCHLING REINFORCES SECURITY COMMITMENT WITH TYPE 2 SOC 2

Benchling | January 27, 2023

news image

On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer com...

Read More
news image

Cell and Gene Therapy

DELFI DIAGNOSTICS SELECTED AS THE LIQUID BIOPSY PARTNER FOR 4-IN-THE-LUNG-RUN: A LARGE-SCALE EUROPEAN LUNG CANCER SCREENING STUDY

Delfi Diagnostics | September 12, 2022

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR. Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their in...

Read More
news image

Research

BIGHAT BIOSCIENCES COMPLETES FIRST STAGE OF RESEARCH COLLABORATION WITH AMGEN

BigHat Biosciences, Inc. | January 12, 2022

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s antibody design platform integrates a high-speed characterization with AI/ML tech...

Read More
news image

RGENTA THERAPEUTICS LAUNCHES WITH $20 MILLION SEED INVESTMENT

BioSpace | April 02, 2020

Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, announced today that it closed a $20 Million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China. Rounding out the series seed syndicate are two additional investors, Kaitai Capital and Legend Star Fund. The company has assembled a world-class team of small-molecule drug developers and an exceptional Scientific A...

Read More
news image

AI

BENCHLING REINFORCES SECURITY COMMITMENT WITH TYPE 2 SOC 2

Benchling | January 27, 2023

On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer com...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us